New hope for EGFR lung cancer: experimental drug SHR-A2009 takes on chemo in phase 3 trial

NCT ID NCT06671379

Ongoing Disease control Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 study compares a new experimental drug, SHR-A2009, to standard chemotherapy in 498 people with advanced EGFR-mutated non-small cell lung cancer whose current targeted therapy (EGFR TKI) has stopped working. The goal is to see if SHR-A2009 can better control the cancer and extend life. Participants receive either SHR-A2009 or a chemo combination (pemetrexed plus carboplatin or cisplatin) by IV.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-A2009 (an experimental drug given by IV)
What this could lead to: If it works, this could offer a new treatment option for people with EGFR-mutant lung cancer whose current targeted therapy has stopped working.
What could go wrong: This is a Phase 3 trial, but it's still experimental. The drug may not work better than chemo, and side effects are unknown. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.